CAS 754
Latest Information Update: 04 Oct 1999
Price :
$50 *
At a glance
- Originator Aventis
- Class Anti-ischaemics
- Mechanism of Action Nitric oxide donors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Angina pectoris
Most Recent Events
- 04 Oct 1999 No-Development-Reported for Angina pectoris in Germany (IV)
- 11 Jun 1996 Investigation in Angina pectoris in Germany (IV)